The full content of Annals is available to subscribers

Subscribe/Learn More  >
Original Research |

Nosocomial Outbreak of Klebsiella Infection Resistant to Late-Generation Cephalosporins

Kenneth S. Meyer, MD; Carl Urban, PhD; Janet A. Eagan, BS, RN; Barbara J. Berger, MD; and James J. Rahal, MD
[+] Article, Author, and Disclosure Information

From The New York Hospital Medical Center of Queens (formerly Booth Memorial Medical Center), Flushing, New York; New York University School of Medicine, New York, New York; Albert Einstein College of Medicine, Bronx, New York. Requests for Reprints: James J. Rahal, MD, The New York Hospital Medical Center of Queens, 56-45 Main Street, Flushing, NY 11355. Acknowledgments: The authors thank Arleen Millette Purr for manuscript preparation. Grant Support: By the BMA Medical Foundation, Inc.

Copyright 2004 by the American College of Physicians

Ann Intern Med. 1993;119(5):353-358. doi:10.7326/0003-4819-119-5-199309010-00001
Text Size: A A A

Objective: To describe the epidemiology, antimicrobial susceptibility, and control of widespread ceftazidime-resistant Klebsiella pneumoniae infections in a North American hospital and circumstances that led to delayed detection.

Design: A 2-year epidemiologic, microbiologic, and clinical cohort study.

Setting: A 487-bed general hospital in New York City.

Patients and Clinical Isolates: Patient records were reviewed retrospectively and prospectively. Isolates were obtained from the Clinical Microbiology Laboratory.

Results: Four hundred thirty-two isolates of ceftazidime-resistant Klebsiella pneumoniae were recovered during a 19-month study period. The peak incidence reached 17.3% of all Klebsiella isolates. One hundred fifty-five patients were colonized or infected, representing more than 70 per 1000 average daily census. Infections occurred in 39% of patients from whom ceftazidime-resistant Klebsiella was isolated. These included 14 bacteremias and 17 pulmonary infections among 52 infected patients. The outbreak coincided with increasing use of ceftazidime therapy for multiresistant Acinetobacter infections. Reduction in ceftazidime use and barrier precautions markedly reduced the incidence of colonization and infection. Ceftriaxone, ceftizoxime, cefotaxime, and cephamycins were inhibitory, but not bactericidal, against ceftazidime-resistant Klebsiella and appeared effective by routine disc diffusion tests. In contrast, imipenem provided consistent bactericidal activity. Preliminary studies indicated that the outbreak was caused by one or more plasmid-mediated lactamases.

Conclusions: Nosocomial ceftazidime-resistant Klebsiella pneumoniae may be resistant to the bactericidal activity of all cephalosporins and cephamycins. Such isolates appear susceptible to cephalosporins other than ceftazidime by routine disc diffusion testing. Ineffective therapy, delayed detection of resistance, and epidemic spread are potential consequences. Imipenem provides consistent bactericidal activity. Ceftazidime restriction and barrier precautions for colonized and infected patients are effective control measures.


Grahic Jump Location
Figure 1.
Incidence of ceftazidime-resistant Klebsiella pneumoniae.Klebsiella pneumoniae

Incidence rate of patients colonized with ceftazidime-resistant from September 1989 to October 1990.

Grahic Jump Location
Grahic Jump Location
Figure 2.
Use of restricted antibiotics.

Number of patients for whom ceftazidime, imipenem/cilastatin, or ceftriaxone was approved from January 1988 to April 1990.

Grahic Jump Location




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Buy Now for $32.00

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Related Articles
Related Point of Care
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.